Synopsis

If Torrent Pharma were to acquire Cipla, which is 2.5 times its size in sales, it would be a bold move. While the acquisition would catapult Torrent to the top of the heap in the domestic market and make it the second-largest Indian pharma company in terms of revenue, financing the deal and integration can pose a litany of challenges.

A historic takeover in the Indian pharmaceutical sector is on the cards. A company that was seen as one of India’s strongest and identified as the country’s pride is at the centre of frenetic moves. Built arduously over nine decades, Cipla founders, the Hamied family, are seeking out buyers. The frontrunner in the race is Ahmedabad-based Torrent Pharmaceuticals, part of the power-to-pharmaceuticals group run by brothers Sudhir Mehta and Samir

  • FONT SIZE
  • SAVE
  • PRINT
  • COMMENT

Uh-oh! This is an exclusive story available for selected readers only.

Worry not. You’re just a step away.

Why ?

  • Exclusive Economic Times Stories, Editorials & Expert opinion across 20+ sectors

  • Stock analysis. Market Research. Industry Trends on 4000+ Stocks

  • Clean experience with
    Minimal Ads

  • Comment & Engage with ET Prime community

  • Exclusive invites to Virtual Events with Industry Leaders

  • A trusted team of Journalists & Analysts who can best filter signal from noise

  • ​Get 1 Year Complimentary Subscription of TOI+ worth Rs.799/-​

By admin

Related Post

Leave a Reply

Your email address will not be published. Required fields are marked *